奥沙利铂联合卡培他滨或替吉奥治疗晚期胃癌的效果

Efficacy of Oxaliplatin with Cappeitabine or Tegafur in Treatment of Advanced Gastric Cancer

目的:探讨奥沙利铂联合卡培他滨或替吉奥对晚期胃癌的疗效。方法:选取2017年10月-2019年1月在笔者所在医院治疗的晚期胃癌患者84例,根据治疗方案分为观察组(n=41)和对照组(n=43)。观察组给予奥沙利铂联合卡培他滨治疗,对照组给予奥沙利铂联合替吉奥治疗,观察两组近期疗效、不良反应及预后,检查治疗前后血清糖类抗原199(CA199)、癌胚抗原(CEA)及血管内皮生长因子(VEGF)。结果:两组近期疗效比较,差异无统计学意义(P>0.05),观察组治疗后血清CA199、CEA和VEGF分别为(189.28±67.28)mg/L、(20.01±9.88)mg/L和(110.04±31.13)pg/ml,明显低于对照组(P<0.05);观察组手足综合征发生率为73.17%,明显高于对照组(P<0.05),而口腔黏膜炎发生率为41.46%,明显低于对照组(P<0.05);观察组中位生存时间为7个月(95%CI:6.28,7.72),对照组中位生存时为7个月(95%CI:6.22,7.78),比较差异无统计学意义(P>0.05)。结论:奥沙利铂联合卡培他滨或替吉奥对晚期胃癌的疗效相当,且均具有一定毒副作用,临床可酌情选用。

Objective:To investigate the efficacy of Oxaliplatin combined with Capecitabine or Tegafur in the treatment of advanced gastric cancer.Method:A total of 84 patients with advanced gastric cancer treated in our hospital from October 2017 to January 2019 were divided into the observation group (n=41) and the control group (n=43) according to the final treatment plan.The observation group was treated with Oxaliplatin combined with Capecitabine,while the control group was treated with Oxaliplatin combined with Tegafur.The short-term efficacy,adverse reactions and prognosis of the two groups were observed,the serum carbohydrate antigen 199 (CA199),carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) were examined before and after treatment.Result:There was no significant difference in short-term efficacy between the observation group and the control group (P>0.05).After treatment,serum CA199,CEA and VEGF in the observation group were (189.28±67.28) mg/L,(20.01±9.88) mg/L and (110.04±31.13) pg/ml,which were significantly lower than those in the control group (P<0.05).The incidence of hand-foot syndrome in the observation group was 73.17%,which was significantly higher than that in the control group (P<0.05),while the incidence of oral mucositis was 41.46%,which was significantly lower than that in the control group (P<0.05).The median survival time of the observation group was 7 months (95%CI:6.28,7.72) in the observation group and 7 months (95%CI:6.22,7.78) in the control group,with no significant difference (P>0.05).Conclusion:Oxaliplatin combined with Capecitabine or Tegafur has similar efficacy in the treatment of advanced gastric cancer and both have certain toxic and side effects,which can be selected as oppropriate in clinic.